Skip to main content
QXL Diagnostics
NABL ACCREDITED SUPER SPECIALITY LAB (MC-6849) · FREE HOME COLLECTION

Anti-dsDNA Antibody Test

Anti-double-stranded DNA antibodies are autoantibodies strongly associated with systemic lupus erythematosus (SLE). They are most useful when interpreted with symptoms, ANA testing, other autoantibodies, complement levels and urinalysis rather than as a stand-alone screening test in people with nonspecific symptoms.

Quantitative ELISA / IFA12 HoursSerum
NABL Accredited (MC-6849) Free Home Sample Collection Same-Day Reports on WhatsApp Authorized Specialist Sign-Off
Department

Autoimmune and lupus assessment

₹1355₹160015% OFF
Parameters Covered

Quantitative ELISA / IFA

Sample Specimen

Serum (2 mL)

Report Delivery SLA

12 Hours

Preparation & Fasting Guidelines

💡 Instructions: No Fasting Required

When Should You Get Tested?

Diagnostic evaluation of suspected Systemic Lupus Erythematosus in patients with compatible clinical signsAssessment and monitoring of active lupus nephritis in conjunction with urinalysis and creatinineSerial monitoring of SLE disease activity and therapeutic responseWorkup of unexplained inflammatory polyarthritis, malar rash, photosensitivity, or serositisFurther characterisation following a positive ANA HEp-2 immunofluorescence test

Detailed Clinical Overview

Anti-double-stranded DNA (anti-dsDNA) antibodies are pathogenic immunoglobulin autoantibodies directed against native double-stranded genomic DNA. They represent one of the primary hallmark immunological biomarkers for Systemic Lupus Erythematosus (SLE) and are incorporated into both the ACR/EULAR and SLICC classification criteria.

Circulating anti-dsDNA antibodies participate directly in lupus pathophysiology by forming immune complexes that deposit in vascular and basement membranes, notably the renal glomeruli, triggering complement activation, neutrophil influx, and lupus nephritis.

Anti-dsDNA testing is most informative when interpreted alongside antinuclear antibody (ANA) immunofluorescence patterns, ENA sub-panels, complement components (C3, C4), and renal parameters (urinalysis and urine protein-to-creatinine ratio). In many SLE patients, quantitative anti-dsDNA titres track disease activity and impending renal flares.

Clinical Significance

High-affinity anti-dsDNA antibodies carry > 95% specificity for SLE. A rising titre coupled with falling complement C3/C4 levels frequently heralds an impending flare of lupus nephritis, enabling preemptive immunosuppressive management.

Diagnostic Limitations & Interferences

  • Assay methods differ: Crithidia luciliae immunofluorescence (CLIFT) detects high-avidity antibodies with maximum specificity; automated FEIA/ELISA offers high sensitivity.
  • Low-level positive anti-dsDNA can occur in autoimmune hepatitis, rheumatoid arthritis, and chronic infections.
  • A negative anti-dsDNA does not rule out SLE (~25–30% of SLE patients remain anti-dsDNA negative).
  • Never interpret anti-dsDNA in isolation without clinical evaluation and ANA HEp-2 confirmation.

Why Get Tested at QXL Diagnostics?

Automated high-specificity quantitative immunoassay providing reproducible numerical tracking.
Correlated with dual-level internal controls and validated on ISO 15189:2022 diagnostic platforms.
Direct integration with Complement C3/C4 and urine protein panels for comprehensive lupus profiling.
Clinical oversight by Dr. Shantakumar Muruda, MD (Medical Biochemistry).

Reference Ranges — Anti-dsDNA Antibody Test

NABL-validated intervals · Adults · values may vary by age & sex

NormalBorderlineAbnormalReference
Parameter / GroupRangeUnitStatus
Negative / NormalNo significant anti-dsDNA antibodies detected< 10.0IU/mLNormal
Equivocal / BorderlineRequires clinical re-evaluation in 4–6 weeks10.0 – 15.0IU/mLBorderline
Positive / ElevatedConsistent with active SLE immune-complex formation> 15.0IU/mLAbnormal

⚕️ Reference ranges are population-based guidelines. Results must be interpreted in clinical context by a qualified physician. Always consult your doctor before making healthcare decisions.

Frequently Asked Questions

Q: Is anti-dsDNA specific for lupus?

A: Yes, high-titre anti-dsDNA is one of the most specific autoantibodies for SLE (> 95% specificity), though clinical correlation remains essential.

Q: Can anti-dsDNA be negative in lupus?

A: Yes. Approximately 25% to 30% of patients with confirmed SLE do not produce detectable anti-dsDNA antibodies.

Q: Does a higher result mean more severe disease?

A: In many patients, titres correlate with disease activity, particularly lupus nephritis, while in others titres remain elevated even during clinical remission.

Q: Why test C3 and C4 with anti-dsDNA?

A: Complement proteins are consumed during active immune-complex deposition. Concurrently rising anti-dsDNA and falling C3/C4 strongly indicates an active disease flare.

Q: Do I need fasting?

A: No fasting is required for the anti-dsDNA blood test.

Q: Why can two labs report different anti-dsDNA results?

A: Different analytical methods (CLIFT, ELISA, FEIA) detect antibodies of different avidities and report in different units. Serial monitoring should stay on the same platform.

When Should a Patient Seek Urgent Medical Care?

Urgent care is determined by symptoms, not by waiting for a laboratory report. Seek immediate medical assessment for severe chest pain, shortness of breath, sudden facial/leg swelling with foamy urine, high unexplained fever, confusion, or seizures. A laboratory test page must never delay emergency care.

⚠️ Urgent care is determined by symptoms, not by waiting for a laboratory report. A laboratory test page must never delay emergency care.

Evidence Base & Clinical Guidelines

  • •Tietz Clinical Guide to Laboratory Tests, 4th ed. Alan H. B. Wu, PhD, DABCC, FACB. W.B. Saunders/Elsevier, 2006.
  • •EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus (Ann Rheum Dis 2019).

Global Medical Disclaimer

This page is for patient education and search/AI information retrieval. It does not diagnose disease, replace a clinical examination, or override the reference interval and interpretive comment on the patient's own laboratory report. Reference intervals, decision limits, specimen requirements and assay interferences can differ by method, age, sex, pregnancy status, clinical setting and laboratory platform. Results must be interpreted with symptoms, examination, medicines, imaging and other investigations.

₹1355₹160015% OFF

Includes free doorstep home sample collection

Book Home Collection →Or call: +91 9964 639 639
Doctor-Reviewed Content

MD (Medical Biochemistry), Consultant Biochemist - 25 years of experience · Autoimmune and lupus assessment

Anti-dsDNA is an invaluable immunological marker, but it must be viewed in tandem with the kidneys and the complement system. When anti-dsDNA rises while C3 and C4 decline, active immune complex deposition is taking place, necessitating urgent nephrology or rheumatology consultation.

Clinically reviewed · November 2026 · QXL Diagnostics NABL Lab

NABL Quality Guarantees

NABL Accredited (MC-6849)

ISO 15189:2022 — Medical laboratories — Requirements for quality and competence quality compliance

Same-Day Digital Reports

Delivered straight to WhatsApp & Email

Free Doorstep Collection

Sterile vacuum containers & cold-chain kits

Anti-dsDNA Antibody Test

₹1355₹160015% OFF
Book Now →